Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120204 | 0.96 | TBXAS1 (0.50) | TBXAS1KDM4ETP53TSHREGLN3 | |
| SCHEMBL25948430 | 0.89 | TBXAS1 (0.59) | TBXAS1KDM4ETP53ALDH1A1PRKCI | |
| Imidazole SCHEMBL11011481 | 0.87 | TBXAS1 (0.42) | TBXAS1KDM4ETP53TSHREGLN3 | |
| SCHEMBL21408418 | 0.85 | TBXAS1 (0.58) | TBXAS1KDM4ETP53TSHREGLN3 | |
| SCHEMBL21408577 | 0.85 | TBXAS1 (0.58) | TBXAS1KDM4ETP53TSHREGLN3 | |
| SCHEMBL8600458 | 0.80 | TBXAS1 (0.52) | TBXAS1KDM4ETP53TSHREGLN3 | |
| SCHEMBL12105110 | 0.79 | — | — | |
| Diethyl Sulfide SCHEMBL31278250 | 0.79 | TBXAS1 (0.47) | TBXAS1KDM4EEGLN3ALDH1A1PRKCI | |
| SCHEMBL8495419 | 0.79 | TBXAS1 (0.60) | TBXAS1KDM4ETP53TSHREGLN3 | |
| SCHEMBL9046908 | 0.78 | TBXAS1 (0.50) | TBXAS1KDM4ETP53TSHREGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493511-B2 | Cyclosporin analogs | ALLERGAN, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | ALLERGAN, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20120088734-A1 | Cyclosporin Analogs | ALLERGAN, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-1730167-B1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INT (DE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2005070955-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| US-4528195-A | Imidazole derivatives and salts thereof, their synthesis and intermediates and pharmaceutical formulations | THOROGOOD PETER B (GB) | 1985-07-09 | — | — | US | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4416895-A | ANTICOAGULANTS, ANTISHOCK AGENTS | BURROUGHS WELLCOME CO. (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065433-A1 | CYCLOSPORIN ANALOGS | CHP1, TSLP, PPP3R1 | TBXAS1 483/4885KDM4E 4669/4885TP53 1195/4885 |
| US-20120088734-A1 | Cyclosporin Analogs | CHP1, TSLP, PPP3R1 | TBXAS1 483/4885KDM4E 4669/4885TP53 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.